Subsequent research should corroborate these results via biochemical assays of mTOR phosphorylation (p-mTOR, p70S6K, 4EBP1) and assess the synergistic efficacy of medicarpin in conjunction with FGFR2 or IDH1 inhibitors in CCA cell and xenograft models. This evidence concerns the gene EIF4EBP1 and cholangiocarcinoma.